EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens for Mycobacterium abscessus lung disease

Sanjay Singh iD, Avneesh Shrivastava, Gunavanthi D Boorgula, Mary C Long, Brian Robbins, Pamela J McShane, Tawanda Gumbo iD, Shashikant Srivastava iD

Antimicrobial Agents and Chemotherapy · 06.05.2026 · 70 (5)

DOI: 10.1128/aac.01437-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.05.2026. Verfasst von Sanjay Singh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA. Hauptthemen laut MEDLINE: Ceftriaxone, Sulbactam, Anti-Bacterial Agents, Mycobacterium abscessus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cystic Fibrosis Foundation Therapeutics, NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The guideline-based therapy achieves sputum culture conversion rates in 20%–34% of patients with Mycobacterium abscessus (MAB) lung disease (LD). Double-β-lactam combinations have been proposed to improve cure based on time-kill curves. We tested MICs followed by hollow fiber system model of MAB (HFS-MAB) exposure-effect studies with sulbactam-durlobactam administered every 8 h (q8h), q12h, and q24h, to identify target exposures. Next, the sulbactam-durlobactam target exposure plus ceftriaxone was administered in the HFS-MAB inoculated with three different MAB isolates, as was the sulbactam-durlobactam-ceftriaxone combination with epetraborole and omadacycline (SDCEO). γ -slopes (kill-speed) were calculated for all regimens. The minimal sulbactam-durlobactam clinical doses that achieved target exposure were identified using Monte Carlo experiments. Ceftriaxone reduced sulbactam-durlobactam MICs by eight-tube dilutions. In the HFS-MAB, sulbactam-durlobactam microbial kill and antimicrobial resistance were linked to % time concentration persists above MIC (%T MIC ), with target exposure of 50%T MIC . Sulbactam-durlobactam killed 3.85 log 10 CFU/mL below day 0 burden ( B 0 ) with regrowth. Sulbactam-durlobactam plus ceftriaxone killed without regrowth and demonstrated Bliss additivity. The kill slope of bacterial population in >95% of virtual subjects was 2.28 (0.97–4.80) log 10 CFU/mL/day for sulbactam-durlobactam-ceftriaxone and 2.91 (1.65–4.93) log 10 CFU/mL/day for SDCEO. The optimal sulbactam-durlobactam dose co-administered with ceftriaxone was 2G q8h for creatinine clearance >90 mL/min (or 4G q12h for outpatients), 2G q12h for 60–90 mL/min, 1G q12h for ≥30 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftriaxoneSulbactamAnti-Bacterial AgentsMycobacterium abscessusAzabicyclo CompoundsMycobacterium Infections, NontuberculousLung DiseasesMicrobial Sensitivity TestsHumansDrug Therapy, Combination

Stichwörter der Autor:innen

probability of target attainmenttarget redundancyγ slopes“double-double” β-lactam-β-lactamase inhibitors

Substanzen

CeftriaxoneSulbactamAnti-Bacterial AgentsAzabicyclo Compoundsdurlobactam

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.
  • Advanta Genetics, Tyler, Texas, USA.
  • Section of Pulmonary and Critical Care, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.
  • IMPI Group of Companies, Mt. Hampden, Zimbabwe.
  • Phase Advance, Dallas, Texas, USA.
  • Department of Cellular and Molecular Biology, University of Texas Health Science Centre at Tyler, Tyler, Texas, USA.

ORCID-Profile: Sanjay Singh, Tawanda Gumbo, Shashikant Srivastava

Förderung

  • Cystic Fibrosis Foundation Therapeutics
  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NICHD NIH HHS

Zitieren

APA

Singh, S., Shrivastava, A., Boorgula, G. D., Long, M. C., Robbins, B., McShane, P. J., Gumbo, T., & Srivastava, S. (2026). Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens for Mycobacterium abscessus lung disease. Antimicrobial Agents and Chemotherapy, 70(5). https://doi.org/10.1128/aac.01437-25

Vancouver

Singh S, Shrivastava A, Boorgula GD, Long MC, Robbins B, McShane PJ, et al. Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens for Mycobacterium abscessus lung disease. Antimicrobial Agents and Chemotherapy. 2026;70(5). doi:10.1128/aac.01437-25

BibTeX
@article{Singh2026,
  author = {Singh, Sanjay and Shrivastava, Avneesh and Boorgula, Gunavanthi D and Long, Mary C and Robbins, Brian and McShane, Pamela J and Gumbo, Tawanda and Srivastava, Shashikant},
  title = {Sulbactam-durlobactam plus ceftriaxone dosing and novel treatment regimens for Mycobacterium abscessus lung disease},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {5},
  doi = {10.1128/aac.01437-25}
}
Kostenlos starten →